All In Biotech

Drug Trial Radar · NCT01808573

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 621 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

621

Actual

Start

Mar 29, 2013

Primary completion

Sep 28, 2018

Study completion Dec 9, 2019

Sponsor

Lead sponsor
Puma Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Mar 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in HER2+ MBC patients who have received two or more prior HER2 directed regimens in the metastatic setting.

Conditions

  • HER2+ Metastatic Breast Cancer (MBC)

Interventions

  • neratinibDrug

  • capecitabineDrug

  • lapatinibDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Centrally Assessed Progression Free SurvivalTime frame: From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.
  2. Overall SurvivalTime frame: From randomization date to death, assessed up to 59 months.The result is based on primary analysis data cut.

Locations

252 sites in 28 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Centers

    Chandler, Arizona

  • Ironwood Cancer and Research Centers

    Gilbert, Arizona

  • Ironwood Cancer and Research Centers

    Mesa, Arizona

  • Ironwood Cancer and Research Centers

    Scottsdale, Arizona

  • UCLA Hematology Oncology

    Alhambra, California

  • CBCC Global Research, Inc. at Comprehensive Blood and Caner Center

    Bakersfield, California

  • Compassionate Cancer Care Medical Group Inc.

    Fountain Valley, California

  • St. Jude Heritage Medical Group

    Fullerton, California

  • St. Jude Heritage Medical Group

    Fullerton, California

  • Marin Cancer Care, Inc.

    Greenbrae, California

  • UCLA Hematology Oncology

    Irvine, California

  • University of California San Diego Medical Center

    La Jolla, California

  • University of California San Diego Moores Cancer Center

    La Jolla, California

  • Breastlink Medical Group, Inc.

    Orange, California

  • UCLA Hematology Oncology

    Pasadena, California

  • UCLA Hematology Oncology

    Porter Ranch, California

  • Emad Ibrahim, MD

    Redlands, California

  • Cancer Care Associates Medical Group, Inc

    Redondo Beach, California

  • Compassionate Cancer Care Medical Group

    Riverside, California

  • University of California San Diego Medical Center - Hillcrest

    San Diego, California

  • Sharp Memorial Hospital

    San Diego, California

  • Breastlink Medical Group, Inc.

    Santa Ana, California

  • Cancer Center of Santa Barbara Sansum Clinic

    Santa Barbara, California

  • Central Coast Medical Oncology

    Santa Maria, California

  • UCLA Hematology Oncology

    Santa Monica, California

  • Cancer Center of Santa Barbara

    Solvang, California

  • UCLA Healthcare Santa Clarita Oncology

    Valencia, California

  • UCLA Hematology/Oncology

    Westlake Village, California

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • Broward Medical Oncology Office

    Plantation, Florida

  • Florida Cancer Research Institute

    Plantation, Florida

  • Emory University Hospital Midtown

    Atlanta, Georgia

  • Emory Clinic

    Atlanta, Georgia

  • Emory University Winship Cancer Institute

    Atlanta, Georgia

  • OnCare Hawaii

    Honolulu, Hawaii

  • Queen's Medical Center

    Honolulu, Hawaii

  • Straub Clinic and Hospital

    Honolulu, Hawaii

  • University of Hawaii Cancer Center

    Honolulu, Hawaii

  • Resurrection Medical Group

    Chicago, Illinois

  • North Shore Oncology-Hematology Associates, Ltd.

    Crystal Lake, Illinois

Showing 40 of 252 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.